secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2022-10-31T23:59:59+00:00
Accession:  0001193125-22-273358
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phoenix Biotech SPAC to merge with Intrinsic Medicine in all-stock deal
-----------------------------------------------------------------------

- Consideration: 13.6M shares of Class A common stock to Intrinsic equity holders.
- Intrinsic is a preclinical-stage therapeutics company using synthetic biology to develop human milk oligosaccharide medicines.
- Closing requires at least $15M available cash (trust + PIPE), Nasdaq listing, and stockholder approvals.
- Sponsor and key Intrinsic stockholders agree to vote in favor; lock-up 180 days or $12.50 price trigger.
- Post-combination company to be led by executives Martinez, Ferrone, Chuang, and Crawford.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000119312522273358/0001193125-22-273358-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000119312522273358/d417140d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-273358

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer